SCHEMBL10244724

SCHEMBL10244724

CNC(=O)NC1CCN(C(C)c2ccccc2OC)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.48
MAPT P10636 1/20 0.46
ALDH1A1 P00352 1/20 0.44
KDM4D Q6B0I6 2/20 0.42
KDM5A P29375 2/20 0.40
HTR7 P34969 2/20 0.40
MTNR1A P48039 2/20 0.40
MTNR1B P49286 2/20 0.40
HTR1A P08908 1/20 0.40
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA4 P22748 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282645 0.84 MCHR1 (0.41) MCHR1MAPTKDM4DHTR7HTR1A
SCHEMBL12566115 0.78 MCHR1 (0.39) MCHR1MAPTALDH1A1KDM4DHTR7
SCHEMBL12566127 0.78 MCHR1 (0.39) MCHR1MAPTALDH1A1KDM4DHTR7
SCHEMBL10244752 0.78 DRD2 (0.42) MCHR1ALDH1A1HTR7HTR1ADRD2
SCHEMBL12608606 0.78 DRD2 (0.42) MCHR1ALDH1A1HTR7HTR1ADRD2
SCHEMBL12303925 0.78 KMT2A (0.40) MCHR1ALDH1A1MTNR1AMTNR1B
SCHEMBL12251141 0.78 KCNA3 (0.40) MCHR1ALDH1A1MTNR1AMTNR1B
SCHEMBL13553415 0.76 CHRM2 (0.44) MAPT
SCHEMBL334807 0.73 CHRM2 (0.41) ALDH1A1HTR1ACA1CA2DRD2
SCHEMBL1132838 0.73 CHRM2 (0.41) ALDH1A1HTR1ACA1CA2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MCHR1 344/4885MAPT 4302/4885ALDH1A1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.